Do glycoprotein IIb/IIIa inhibitors interact with assays for myocardial necrosis?

Clin Biochem. 2003 Nov;36(8):663-6. doi: 10.1016/s0009-9120(03)00112-7.

Abstract

Objectives: To determine whether glycoprotein (GP) IIB/IIIA inhibitors interact with cardiac marker assays: total creatine kinase (CK), CK-MB, and troponin-I (TnI).

Design and methods: Two blood samples were collected during coronary angiography or angioplasty and analyzed for cardiac markers: one after arterial sheath insertion and the second 10 mins later. In the first phase (n=101), heparin and GP IIb/IIIa inhibitors were given between samples, in the second phase (n=45) only heparin was given, and in the third phase (n=54) neither drug was given.

Results: In each phase, there was a significant decline in total CK over the 10 min period. There were no consistent significant changes in CK-MB or TnI.

Conclusions: Neither GP IIb/IIIa inhibitors nor i.v. heparin interact with cardiac marker assays. There is a small but significant decline in total CK levels within 10 mins of arterial puncture that is unrelated to administration of these drugs.

Publication types

  • Comparative Study

MeSH terms

  • Abciximab
  • Antibodies, Monoclonal / pharmacokinetics
  • Antibodies, Monoclonal / pharmacology
  • Biomarkers / blood
  • Drug Interactions / physiology
  • Heparin / pharmacokinetics
  • Heparin / pharmacology
  • Humans
  • Immunoglobulin Fab Fragments / pharmacology
  • Myocardium / pathology*
  • Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors*
  • Platelet Glycoprotein GPIIb-IIIa Complex / metabolism

Substances

  • Antibodies, Monoclonal
  • Biomarkers
  • Immunoglobulin Fab Fragments
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Heparin
  • Abciximab